12:00 AM
 | 
Mar 01, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cerezyme imiglucerase regulatory update

The European Medicines Agency's CHMP advised that patients continue to follow interim recommendations for use of Cerezyme imiglucerase to treat Gaucher's disease and Fabrazyme agalsidase beta to treat Fabry's disease after Genzyme informed the agency that...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >